{"id":34706,"date":"2025-09-26T12:37:30","date_gmt":"2025-09-26T05:37:30","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=34706"},"modified":"2025-09-26T12:37:30","modified_gmt":"2025-09-26T05:37:30","slug":"jacobio-chairman-and-concerted-parties-increase-shareholding-by-nearly-hk100-million-demonstrating-confidence-in-long-term-growth","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=34706","title":{"rendered":"Jacobio Chairman and Concerted Parties Increase Shareholding by Nearly HK$100 Million, Demonstrating Confidence in Long-term Growth"},"content":{"rendered":"

BEIJING<\/span>, SHANGHAI<\/span> and BOSTON<\/span><\/span>, Sept. 26, 2025<\/span><\/span> \/PRNewswire\/ — Jacobio Pharmaceuticals (1167.HK) today<\/span> announced that its Chairman and Chief Executive Officer, Dr. Yinxiang Wang, together with concerted parties, have recently increased their shareholding in the Company by 11.06 million shares, representing a total investment of approximately HK$96.34 million<\/span>. This action underscores their strong confidence in the Company’s long-term growth prospects.<\/p>\n

In addition, the Company’s share repurchase plan with an upper limit of HK$100 million<\/span>, which was approved by the Board in July 2025<\/span>, has already led to the repurchase of 326,400 shares, with a cumulative payment of HK$2.67 million<\/span>. The Company will continue to implement the repurchase plan based on market conditions.<\/p>\n

In the interim results for 2025 released earlier, Jacobio reported multiple encouraging R&D achievements. The Company continues to focus on two major R&D pillars \u2013 KRAS and iADC \u2013 with core programs making steady progress, further demonstrating Jacobio’s competitiveness and growth potential in the global biopharmaceutical sector.<\/p>\n

Within the KRAS pathway, Jacobio has established a comprehensive development strategy. In May 2025<\/span>, the Company’s KRAS G12C inhibitor, Glecirasib, was approved by the National Medical Products Administration (NMPA) for second-line monotherapy in KRAS G12C mutant non-small cell lung cancer (NSCLC) and successfully launched in China<\/span>. This milestone not only marked Jacobio’s first commercial entry into the Chinese market but also triggered a milestone payment of RMB 50 million<\/span> from its partner Allist. At the same time, Glecirasib is being evaluated in combination with the SHP2<\/span> inhibitor sitneprotafib for first-line NSCLC.<\/p>\n

Beyond its marketed product, Jacobio’s pan-KRAS inhibitor JAB-23E73 has shown important progress. In the dose-escalation phase of its Phase I clinical trial, multiple confirmed partial responses (PRs) have been observed, with favorable safety and pharmacokinetic (PK) profiles consistent with expectations. Full Phase I data are expected to be released in the first half of 2026, which will mark a critical milestone for the global pan-KRAS landscape. Meanwhile, the Company is actively advancing next-generation KRAS inhibitors. The EGFR-KRAS G12D tADC project, which utilizes EGFR as the targeting antibody and KRAS G12D as the payload to enable precise and efficient treatment, is expected to submit an IND application in the second half of 2026.<\/p>\n

In its other R&D pillar, iADC, Jacobio also maintains a leading position. The Company is developing JAB-BX467, a HER2-STING iADC candidate. By using a STING agonist as the payload, this innovative program is designed to convert “cold tumors” into “hot tumors,” offering a novel treatment option for solid tumors where PD-1 monotherapy has limited efficacy. The program is currently at the preclinical stage, with IND submission planned for the second half of 2026.<\/p>\n

As an innovation-driven biotechnology company, Jacobio is already positioned among the global leaders in KRAS and iADC research, with a clear development roadmap and significant commercial potential. The Company believes that its current share price does not fully reflect the value of its pipeline or its long-term growth potential. The decision by the Chairman and concerted parties to increase their shareholding by nearly HK$100 million<\/span> not only demonstrates the strong alignment of interests between management and shareholders but also underscores their unwavering confidence in the Company’s long-term value creation.<\/p>\n

About Jacobio Pharma<\/p>\n

Jacobio Pharma (1167.HK) is committed to providing breakthrough treatments for patients. With an induced allosteric drug discovery platform, the company’s core projects focus on the KRAS pathway. The company envisions becoming a global leader in research and development, fostering strategic partnerships to drive innovation. Jacobio’s\u00a0 R&D centers are in Beijing<\/span>, Shanghai<\/span> (China<\/span>), and Boston<\/span> (USA<\/span>). Clinical trials are conducted at over 180 sites in China<\/span>, more than 30 sites in the USA<\/span>, and over 10 sites across several European countries. For more information, please visit: http:\/\/www.jacobiopharma.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n

BEIJING<\/span>, SHANGHAI<\/span> and BOSTON<\/span><\/span>, Sept. 26, 2025<\/span><\/span> \/PRNewswire\/ — Jacobio Pharmaceuticals (1167.HK) today<\/span> announced that its Chairman and Chief Executive Officer, Dr. Yinxiang Wang, together with concerted parties, have recently increased their shareholding in the Company by 11.06 million shares, representing a total investment of approximately HK$96.34 million<\/span>. This action underscores their strong confidence in the Company’s long-term growth prospects.<\/p>\n

In addition, the Company’s share repurchase plan with an upper limit of HK$100 million<\/span>, which was approved by the Board in July 2025<\/span>, has already led to the repurchase of 326,400 shares, with a cumulative payment of HK$2.67 million<\/span>. The Company will continue to implement the repurchase plan based on market conditions.<\/p>\n

In the interim results for 2025 released earlier, Jacobio reported multiple encouraging R&D achievements. The Company continues to focus on two major R&D pillars \u2013 KRAS and iADC \u2013 with core programs making steady progress, further demonstrating Jacobio’s competitiveness and growth potential in the global biopharmaceutical sector.<\/p>\n

Within the KRAS pathway, Jacobio has established a comprehensive development strategy. In May 2025<\/span>, the Company’s KRAS G12C inhibitor, Glecirasib, was approved by the National Medical Products Administration (NMPA) for second-line monotherapy in KRAS G12C mutant non-small cell lung cancer (NSCLC) and successfully launched in China<\/span>. This milestone not only marked Jacobio’s first commercial entry into the Chinese market but also triggered a milestone payment of RMB 50 million<\/span> from its partner Allist. At the same time, Glecirasib is being evaluated in combination with the SHP2<\/span> inhibitor sitneprotafib for first-line NSCLC.<\/p>\n

Beyond its marketed product, Jacobio’s pan-KRAS inhibitor JAB-23E73 has shown important progress. In the dose-escalation phase of its Phase I clinical trial, multiple confirmed partial responses (PRs) have been observed, with favorable safety and pharmacokinetic (PK) profiles consistent with expectations. Full Phase I data are expected to be released in the first half of 2026, which will mark a critical milestone for the global pan-KRAS landscape. Meanwhile, the Company is actively advancing next-generation KRAS inhibitors. The EGFR-KRAS G12D tADC project, which utilizes EGFR as the targeting antibody and KRAS G12D as the payload to enable precise and efficient treatment, is expected to submit an IND application in the second half of 2026.<\/p>\n

In its other R&D pillar, iADC, Jacobio also maintains a leading position. The Company is developing JAB-BX467, a HER2-STING iADC candidate. By using a STING agonist as the payload, this innovative program is designed to convert “cold tumors” into “hot tumors,” offering a novel treatment option for solid tumors where PD-1 monotherapy has limited efficacy. The program is currently at the preclinical stage, with IND submission planned for the second half of 2026.<\/p>\n

As an innovation-driven biotechnology company, Jacobio is already positioned among the global leaders in KRAS and iADC research, with a clear development roadmap and significant commercial potential. The Company believes that its current share price does not fully reflect the value of its pipeline or its long-term growth potential. The decision by the Chairman and concerted parties to increase their shareholding by nearly HK$100 million<\/span> not only demonstrates the strong alignment of interests between management and shareholders but also underscores their unwavering confidence in the Company’s long-term value creation.<\/p>\n

About Jacobio Pharma<\/p>\n

Jacobio Pharma (1167.HK) is committed to providing breakthrough treatments for patients. With an induced allosteric drug discovery platform, the company’s core projects focus on the KRAS pathway. The company envisions becoming a global leader in research and development, fostering strategic partnerships to drive innovation. Jacobio’s\u00a0 R&D centers are in Beijing<\/span>, Shanghai<\/span> (China<\/span>), and Boston<\/span> (USA<\/span>). Clinical trials are conducted at over 180 sites in China<\/span>, more than 30 sites in the USA<\/span>, and over 10 sites across several European countries. For more information, please visit: http:\/\/www.jacobiopharma.com<\/a><\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-34706","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/34706","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34706"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/34706\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34706"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34706"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34706"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}